# Radiofrequency Ablation Combined With Toripalimab and Lenvatinib in the Treatment of Short-term Recurrent Hepatocellular Carcinoma.

> **NCT05162898** · NA · UNKNOWN · sponsor: **Henan Cancer Hospital** · enrollment: 90 (estimated)

## Conditions studied

- Recurrent Hepatocellular Cancer

## Interventions

- **DRUG:** toripalimab
- **DRUG:** Lenvatinib
- **DEVICE:** Radiofrequency ablation

## Key facts

- **NCT ID:** NCT05162898
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01
- **Primary completion:** 2023-12
- **Final completion:** 2025-12
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2022-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05162898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05162898, "Radiofrequency Ablation Combined With Toripalimab and Lenvatinib in the Treatment of Short-term Recurrent Hepatocellular Carcinoma.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05162898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*